Publications by authors named "Amal Jabareen"
Article Synopsis
- The study aimed to assess whether monitoring anti-Xa levels and adjusting enoxaparin doses in pregnant women could reduce complications related to the placenta during pregnancy.
- Out of 585 women evaluated, 110 were included, with significant differences in dosage adjustments and outcomes between the group receiving anti-Xa monitoring and the control group who were dosed by weight only.
- Results indicated that monitored women had more term deliveries and showed trends toward larger birth weights and fewer complications, but larger studies are necessary to confirm these findings.
Background: Despite the beneficial effects of glycoprotein (GP) IIb/IIIa antagonists in patients with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), GP IIb/IIIa antagonists are rarely administered in general internal medicine wards in Israel, where most patients with UA/ NSTEMI are admitted, due to lack of adequate monitoring and safety concerns.
Objective: The aims of this study were to compare the prevalence of bleeding complications in patients with UA/NSTEMI receiving combination treatment with eptifibatide (a GP IIb/IIIa antagonist), the low-molecular-weight heparin enoxaparin, and acetylsalicylic acid (ASA) versus that in patients receiving enoxaparin and ASA in internal medicine wards in Israel, and to identify risk factors for bleeding complications.
Methods: This retrospective analysis included information from the database at Rambam Medical Center, Haifa, Israel.